Inbeeo

🌱𝗜-𝗟𝗔𝗦 𝗥𝗲𝗰𝗮𝗽 #𝟰: 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗖𝗵𝗮𝗻𝗴𝗲: 𝗖𝗦𝗥 𝗶𝗻 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 🌱 At Inbeeo’s ‘Leaders in Access Summit 2024’, senior pricing and market access leaders joined Inbeeo and we explored how 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗦𝗼𝗰𝗶𝗮𝗹 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 (𝗖𝗦𝗥) is increasingly shaping equitable and sustainable access strategies. Here are some of the key takeaways from our discussions: 🔑 𝗖𝗦𝗥, 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆, 𝗮𝗻𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗮𝗿𝗲 𝗱𝗲𝗲𝗽𝗹𝘆 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗲𝗱. While structures vary, mature organizations embed CSR into global and regional teams, integrating this ever-important consideration across the product lifecycle to ensure societal and patient impact. 📊 𝗠𝗲𝗮𝘀𝘂𝗿𝗲𝗺𝗲𝗻𝘁 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝗮 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲. While CSR KPIs exist in some direct markets and for mature brands, gaps persist in distributor-led markets. Companies are leveraging initiatives like the Access to Medicine Index, but stronger benchmarking systems are critical for future progress. 🗣️ 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝘁𝗵𝗲 𝗺𝗶𝘀𝘀𝗶𝗻𝗴 𝗽𝗶𝗲𝗰𝗲. Tailored messaging to stakeholders—patients, policymakers, payers, and advocacy groups—is essential for building trust, elevating industry reputation, and enhancing accountability. Relatable and clear communication on this topic will have an industry-wide impact. 💡 At Inbeeo, we are committed to helping organizations align CSR with their market access strategies and objectives, empowering them to deliver measurable benefits for patients, policymakers, and businesses alike. Reach out to Enzo Straccia or Charlotte Langbo to learn more about our Inbeeo Leaders in Access events for 2025! #CSR #MarketAccess #PatientAccess #Sustainability #LeadersInAcccessSummit #AccessStrategy

🌍 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗔𝗰𝗰𝗲𝘀𝘀 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗧𝗼𝘂𝗿𝗶𝘀𝗺: 𝟱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗔𝗻𝗴𝗹𝗲𝘀 𝘁𝗼 𝗘𝘅𝗽𝗹𝗼𝗿𝗲💡 ✈️ Travelling abroad for medical treatment is on the rise, especially for innovative therapies like cell and gene treatments that are costly and not available everywhere. This phenomenon, known as medical tourism, offers pharma an exciting path to expand access to high-value therapies and tackle global healthcare disparities. 🌐 Despite the growing prominence of medical tourism, many aspects of this growing phenomenon remain undefined, creating both challenges and opportunities. So, where should we start if we want to leverage medical tourism in our market access strategies? Andrea O., Senior Consultant at Inbeeo, highlights five strategic angles to explore: 1.   🌏 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝘆𝗶𝗻𝗴 𝗞𝗲𝘆 𝗗𝗲𝘀𝘁𝗶𝗻𝗮𝘁𝗶𝗼𝗻𝘀: Where is the demand, and which countries offer the best mix of treatment quality and affordability? 2.   💳 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗪𝗵𝗼 𝗣𝗮𝘆𝘀: Who typically covers treatment costs—patients, insurers, employers, or governments—and how can this shape our approach? 3.   📜 𝗠𝗮𝗽𝗽𝗶𝗻𝗴 𝗖𝗿𝗼𝘀𝘀-𝗕𝗼𝗿𝗱𝗲𝗿 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 & 𝗣𝗼𝗹𝗶𝗰𝗶𝗲𝘀: What legal, ethical, and policy considerations must we navigate to ensure smooth market entry and patient access? 4.   💰 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 & 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: What considerations should be made for varying reimbursement systems, government funding models, and patient affordability in different regions? How can we balance profitability with equitable access? 5.   💬 𝗘𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲: How can we support patients at every step—from travel logistics to post-treatment follow-up? These are just a few key questions to kickstart a compelling market access strategy with medical tourism in mind. 🧠 Curious about how medical tourism can benefit your asset(s) or how you can get involved? 💡 Reach out to Andrea O. or drop us a message, and let’s explore the possibilities together! 🤝🌍 What other questions do you think are relevant to explore? We’d love to hear your ideas in the comments! 💭  #Pharma #MarketAccess #MedicalTourism #GlobalHealth #HealthcareInnovation #InnovativeTherapies #PatientCare

🔍🇬🇧  𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗔𝗰𝗰𝗲𝘀𝘀: 𝗨𝗞’𝘀 𝗜𝗟𝗔𝗣 𝗣𝗮𝘁𝗵𝘄𝗮𝘆 𝗥𝗲𝗹𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟱!💡📈 🇬🇧📅 The UK’s Innovative Licensing and Access Pathway (ILAP) is set for a strategic relaunch in Q1 2025. Since its inception in 2021, ILAP has facilitated streamlined access to innovative medicines within the UK. In response to stakeholder feedback and sustainability objectives, the revamped pathway will emphasize selectivity, focusing on transformative medicines that address specific NHS needs. ⏩ Key updates include more stringent entry criteria, enhanced integration with the NHS, MHRA, and HTA bodies, and improved timelines to facilitate earlier patient access. The current ILAP will accept applications until November 20th, 2024, with the new pathway opening in March 2025. Detailed information on the new eligibility and selection criteria, along with the benefits package, will be published in January 2025. The new ILAP will offer a more compelling support package to medicine developers, including : •   🎯 𝗦𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗘𝗻𝘁𝗿𝘆 𝗖𝗿𝗶𝘁𝗲𝗿𝗶𝗮: Ensuring focus on transformative medicines that meet NHS unmet needs. •   🤝 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: Providing a single integrated platform for sustained collaborative working between manufacturers, the regulator (MHRA), UK Health Technology Assessment (HTA) bodies, and the NHS. •   🔄 𝗦𝘁𝗿𝗲𝗮𝗺𝗹𝗶𝗻𝗲𝗱 𝗣𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀: Simplifying the roadmap and offering more predictable timelines to enable stakeholders to plan more effectively. •   🏥 𝗡𝗛𝗦 𝗜𝗻𝘃𝗼𝗹𝘃𝗲𝗺𝗲𝗻𝘁: Direct involvement of the NHS to focus on operational planning and system preparedness for the introduction of innovative new medicines. Find out more here: https://lnkd.in/gx_bvdBg Want to learn more about the ILAP relaunch and what it could mean for your innovative therapies? Reach out to Vishal Yadav and Christel Jansen for more insights! Contributions by Lucrezia Della Loggia, Associate at Inbeeo! #ILAP #MHRA #NHS #UKHealthcare #UKRegulation #DrugDevelopment #PatientAccess #InnovativeTherapies

🔬 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗠𝗥 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗜𝗻𝗯𝗲𝗲𝗼’𝘀 𝗜𝗦𝗣𝗢𝗥 𝟮𝟬𝟮𝟰 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻🌍 🚨 Thank you to everyone who stopped by our Inbeeo poster at ISPOR—The Professional Society for Health Economics and Outcomes Research on 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗶𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲𝘀 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝗨 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀, presented by our consultant Tania Savant! 💡 The discussions sparked by our poster highlighted some fascinating trends and challenges in tackling antimicrobial resistance (AMR). Here are a few key takeaways: ➡️ 𝗖𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗮𝗿𝗲 𝘀𝘁𝗮𝗿𝘁𝗶𝗻𝗴 𝘁𝗼 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗲 𝗔𝗠𝗥: UK, Sweden, Germany and France are great examples, with P&R incentives in place for antibiotics addressing AMR. ➡️ 𝗜𝘁𝗮𝗹𝘆 𝗶𝘀 𝘁𝗮𝗸𝗶𝗻𝗴 𝗶𝘁 𝗮 𝘀𝘁𝗲𝗽 𝗳𝘂𝗿𝘁𝗵𝗲𝗿, providing significant funding to foster research and innovation in AMR. This example underscores the critical role of government support—check out this inspiring initiative from the Italian government contributing $21M to research! https://lnkd.in/epuQctuT. ➡️ 𝗣𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗮𝗿𝗲 𝗮 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱, 𝗯𝘂𝘁 𝘁𝗵𝗲𝘆 𝗮𝗹𝗼𝗻𝗲 𝗮𝗿𝗲 𝗻𝗼𝘁 𝘀𝘂𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁: Manufacturers advocate for stronger, aligned incentives to ensure sustainable antibiotic innovation and market access. The gap between policy ambition and practical implementation remains a challenge. 🌍 Tackling AMR requires 𝗮 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗳𝗳𝗼𝗿𝘁 across policymakers, healthcare systems, and manufacturers. Let’s continue to discuss how we can collectively create sustainable solutions that benefit patients and safeguard public health. Thank you to everyone who joined us and engaged in insightful discussions! If you couldn’t attend but would like to learn more, feel free to reach out—we’d love to connect and share our in-depth findings! Tania Savant Enzo Straccia Herve Lilliu! #AMR #ISPOR2024 #MarketAccess #Inbeeo #Reimbursement #Antibiotics #HealthPolicy  

🇸🇪𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗦𝘄𝗲𝗱𝗲𝗻: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗠𝗮𝗻𝗮𝗴𝗲𝗱 𝗘𝗻𝘁𝗿𝘆 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 (𝗠𝗘𝗔𝘀)🇸🇪 How are MEAs reshaping access to novel therapies in Sweden? In Sweden, MEAs are now central tools for ensuring access to innovative therapies while managing healthcare costs. Currently, 𝗼𝘃𝗲𝗿 𝗵𝗮𝗹𝗳 𝗼𝗳 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗮𝗹𝗲𝘀 𝗮𝗿𝗲 𝗰𝗼𝘃𝗲𝗿𝗲𝗱 𝗯𝘆 𝗠𝗘𝗔𝘀, which often use confidential rebates and outcome-based payments to balance affordability and value. 🔍 𝗛𝗼𝘄 𝗠𝗘𝗔𝘀 𝗪𝗼𝗿𝗸  MEAs complement Sweden’s value-based pricing system for outpatient drugs, addressing uncertainties around costs and patient volumes while allowing flexibility for local needs through three key players: • 𝗧𝗟𝗩 (𝗗𝗲𝗻𝘁𝗮𝗹 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗔𝗴𝗲𝗻𝗰𝘆): Sets national standards for cost-effectiveness and access. • 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘁𝗶𝗲𝘀: Negotiate agreements to align with local budgets and healthcare priorities. • 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀: Collaborate to support both access and cost containment. 🚀 𝗙𝘂𝘁𝘂𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀  With drug costs rising around 5% annually, MEAs are increasingly critical for maintaining sustainable access to high-cost therapies. TLV is exploring new MEA models, including outcome-based payments, to better support advanced therapies. 📊 𝗣𝗼𝗹𝗶𝗰𝘆 𝗮𝗻𝗱 𝗘𝗾𝘂𝗶𝘁𝘆  𝗘𝗾𝘂𝗮𝗹 𝗮𝗰𝗰𝗲𝘀𝘀 is a cornerstone of Sweden’s healthcare system and remains high on the political agenda. While MEAs can accelerate access to innovative therapies, Sweden’s decentralized healthcare model—where regional authorities negotiate MEAs—can lead to variations in access across regions. The government is considering steps to centralize certain aspects of medicine access to ensure equitable access across all regions. 📈 𝗪𝗵𝗮𝘁 𝗧𝗵𝗶𝘀 𝗠𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀  For companies entering the Swedish market, understanding both TLV’s value-based pricing approach and the nuances of regional MEA negotiations is essential. Monitoring policy developments toward national coordination will also be crucial. Balancing cost-effectiveness with equitable access will continue to be fundamental—especially for high-cost, innovative therapies. Interested in navigating MEAs and staying ahead of policy changes in Sweden? 📩 Contact Charlotte Langbo and Elisabetta Cesari to discuss how we can help you navigate these complexities and optimize access to your innovative products in Sweden! Contribution by Elisabetta Cesari, our Senior Associate at Inbeeo! #ManagedEntryAgreements #MarketAccess #InnovativeTherapies #Sweden #EquitableAccess 

🌍 𝗜𝗦𝗣𝗢𝗥 𝗘𝗨 𝟮𝟬𝟮𝟰 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: 𝗦𝘁𝗿𝗶𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗥𝗶𝗴𝗵𝘁 𝗕𝗮𝗹𝗮𝗻𝗰𝗲 𝗕𝗲𝘁𝘄𝗲𝗲𝗻 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗮𝗻𝗱 𝗙𝗮𝗰𝗶𝗹𝗶𝘁𝗮𝘁𝗶𝗻𝗴 𝗨𝗽𝘁𝗮𝗸𝗲 ⚖️💊 Thank you to everyone who attended the Inbeeo podium presentation on Biosimilars delivered by our Senior Consultant Vishal Yadav at ISPOR EU 2024! We are excited to share some key takeaways from our discussion on biosimilars: 🔑 𝗕𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗲𝗱 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗮𝗻𝗱 𝘂𝗽𝘁𝗮𝗸𝗲 is crucial for a healthy biosimilar market. 💡 𝗟𝗼𝘄𝗲𝗿 𝗰𝗼𝘀𝘁𝘀 𝗱𝗼𝗻’𝘁 𝗮𝗹𝘄𝗮𝘆𝘀 𝗺𝗲𝗮𝗻 𝗵𝗶𝗴𝗵𝗲𝗿 𝘂𝗽𝘁𝗮𝗸𝗲. For instance, France has stringent price-setting criteria but the lowest biosimilar uptake among the five markets analysed. ✅In contrast, the 𝗨𝗞 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝘄𝗵𝗶𝗹𝗲 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗺𝗮𝗿𝗸𝗲𝘁 𝗽𝗲𝗻𝗲𝘁𝗿𝗮𝘁𝗶𝗼𝗻. This success is driven by centralized national-level tenders and NHS switching policies. As biosimilar markets mature, pricing policies must be routinely monitored to help prevent excessive price erosion and ensure sustainable adoption. A heartfelt thanks to everyone who attended the presentation and shared their thoughts! If you weren't able to attend but want to connect to hear more, please do reach out to Vishal Yadav, Enzo Straccia, or Herve Lilliu! #Biosimilars #MarketAccess #PricingStrategies #ISPOR2024 #Inbeeo

🎤📋👥𝗜𝗻𝗯𝗲𝗲𝗼'𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝗰𝗲 𝗮𝘁 𝗜𝗦𝗣𝗢𝗥 𝟮𝟬𝟮𝟰!🎤📋👥 In case you did not get a chance to stop by our poster or missed our podium presentation at ISPOR, here is a summary of activities we participated at ISPOR 2024: Our Inbeeo experts were excited to present and discuss some key topics with attendees during the podium and poster presentations, including: 1.   Assessing the Impact of Access Policies on Biosimilar Pricing: A Comparative Study of Five Major European Markets 2.   Reimbursement Incentives for Antibiotics in Eleven European Countries: A Comparative Analysis ✨ Stay tuned for upcoming posts, where we will dive deeper into each of these topics! ✨ Feel free to reach out if you’d like to continue the conversation or have any questions. Thanks to everyone who joined us—we look forward to connecting with you again! #ISPOR #MarketAccess #Inbeeo #HealthEconomics #HTA #Pharma

🎯𝗜-𝗟𝗔𝗦 𝗥𝗲𝗰𝗮𝗽 #𝟯: 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗰𝗰𝗲𝘀𝘀 𝗶𝗻𝘁𝗼 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗠𝗮𝗸𝗶𝗻𝗴 🎯 At the Inbeeo Leaders in Access Summit 2024, we discussed the importance of integrating access into decision-making. It is widely accepted that Market Access has yet to realise its full potential impact across all clinical development stages, particularly in preclinical and phase 1 development. What are the biggest impediments to developing a truly successful market access strategy?   -   Continued perception of Market Access as a specialist function as opposed to a strategic partner  -   Market access is often not represented in key decision forums due to the lack of organisational influence networks   -   Lack of truly effective influence networks and challenge of the Market Access representative to be a ‘listened to’ voice in the room So, how do we think these challenges could be overcome? -   𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗮𝗰𝗰𝗲𝘀𝘀 𝗲𝗱𝘂𝗰𝗮𝘁𝗶𝗼𝗻, for example by requiring Market Access training for progression into corporate leadership roles, which would increase the awareness of access as a strategic function -   𝗦𝗲𝗲𝗸𝗶𝗻𝗴 𝗼𝘂𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗰𝗵𝗮𝗺𝗽𝗶𝗼𝗻𝘀 𝗶𝗻 𝗖-𝘀𝘂𝗶𝘁𝗲, peripheral leadership and governance, hiring more corporate leaders with a background in Market Access would help develop a broader appreciation of the importance of true strategic planning and effective execution  -   𝗠𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗳𝗼𝗿 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗮𝗰𝗰𝗲𝘀𝘀 by implementing early integrated value propositions, and providing clear impact scenarios Stay tuned for the final post from the Leaders in Access Summit on Corporate Social Responsibility in Access Strategy! Reach out to Enzo Straccia or Charlotte Langbo to learn more about our Inbeeo Leaders in Access events for 2025! #Pharmaceuticals #MarketAccess #ILAS #LeadersInAcccessSummit #AccessStrategy

💡 Is "Buy One, Give One" the future of pharmaceutical equity pricing? Marie-Stella-Maris (B Corp) uses this model to fund clean water initiatives. Could pharma adopt a similar approach to balance Global Pharmaceutical Pricing and #ESG objectives? In our latest blog, Christel Jansen explores how pharma companies can align commercial sustainability with equitable access, drawing lessons from outside the industry. 👉 Read more: https://lnkd.in/e7AAYbKX Are you aiming to align your Market Access and ESG goals while expanding global access? Let’s explore how to strategically balance commercial sustainability with equitable access in your market access initiatives. Feel free to connect to start the conversation! #lifesciences #pharmaceuticals #marketacces #patientaccess #globalhealth #accesstomedicines #drugpricing #equitypricing

That's a wrap from ISPOR 2024! 🎉 A fantastic few days for Team Inbeeo as part of the Enosium Life Science group. Wonderful to reconnect with colleagues and make plenty of new connections too! 𝗢𝘂𝗿 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗰𝗼𝗻𝗴𝗿𝗲𝘀𝘀: 1. 𝗝𝗖𝗔 𝗶𝘀 𝗙𝗿𝗼𝗻𝘁 𝗮𝗻𝗱 𝗖𝗲𝗻𝘁𝗿𝗲: With less than 2 months until the JCA, it was a major focus. There's optimism that the JCA will promote transparency and elevate evidence standards across the industry 2. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝘁𝗵𝗲 𝗡𝗮𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗚𝗮𝗺𝗲: There's a clear interest among countries to move towards enhanced cross-border collaboration beyond just HTA, extending into procurement and potentially even pricing! 3. 𝗙𝘂𝘁𝘂𝗿𝗲-𝗣𝗿𝗼𝗼𝗳𝗶𝗻𝗴 𝗶𝘀 𝗕𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴𝗹𝘆 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗳𝗼𝗿 𝗣𝗮𝘆𝗲𝗿𝘀: Payers are better equipped to control prices but recognize the need to future-proof through horizon scanning, safeguarding budgets, and improving management for upcoming challenges 4. 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗳𝗼𝗿 𝗚𝗹𝗼𝗯𝗮𝗹 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗔𝗰𝗰𝗲𝘀𝘀: Ensuring access and affordability of medicines worldwide is gaining momentum. There's a growing need to enhance equity patient access even in regions where HTA frameworks don't currently exist. We are excited to further integrate these insights into our work at Inbeeo and continue contributing to helping you achieve your objectives. Please do contact us to discuss your needs further!